Lyell Immunopharma (NASDAQ:LYEL) Coverage Initiated by Analysts at Citizens Jmp

Citizens Jmp assumed coverage on shares of Lyell Immunopharma (NASDAQ:LYEL) in a research report sent to investors on Monday morning, Marketbeat reports. The brokerage issued a market outperform rating and a $34.00 target price on the stock.

LYEL has been the topic of several other research reports. HC Wainwright raised Lyell Immunopharma from a “neutral” rating to a “buy” rating and upped their price objective for the company from $20.00 to $45.00 in a research report on Tuesday, December 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $39.50.

Lyell Immunopharma Stock Performance

Shares of NASDAQ LYEL opened at $25.50 on Monday. Lyell Immunopharma has a fifty-two week low of $7.65 and a fifty-two week high of $45.00. The company has a market cap of $541.62 million, a price-to-earnings ratio of -1.11 and a beta of -0.14. The business’s 50 day moving average price is $24.64 and its 200-day moving average price is $21.24.

Insider Activity

In related news, COO Stephen J. Hill sold 1,236 shares of the stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $23.39, for a total value of $28,910.04. Following the transaction, the chief operating officer owned 17,795 shares of the company’s stock, valued at $416,225.05. This represents a 6.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Lynn Seely sold 7,455 shares of the firm’s stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $23.39, for a total value of $174,372.45. Following the transaction, the chief executive officer owned 74,266 shares in the company, valued at $1,737,081.74. The trade was a 9.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 11,310 shares of company stock valued at $264,285. Corporate insiders own 22.30% of the company’s stock.

Institutional Investors Weigh In On Lyell Immunopharma

Several hedge funds have recently made changes to their positions in the company. Invesco Ltd. purchased a new position in shares of Lyell Immunopharma during the fourth quarter valued at $3,036,000. MWG Caph Ltd bought a new stake in shares of Lyell Immunopharma in the fourth quarter valued at about $31,030,000. ExodusPoint Capital Management LP purchased a new stake in Lyell Immunopharma in the fourth quarter worth about $262,000. Barclays PLC lifted its stake in Lyell Immunopharma by 1,239.5% in the fourth quarter. Barclays PLC now owns 15,967 shares of the company’s stock worth $491,000 after acquiring an additional 14,775 shares during the period. Finally, Marshall Wace LLP bought a new position in Lyell Immunopharma during the 4th quarter worth about $2,257,000. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.